Metabolic syndrome: do clinical criteria identify similar individuals among overweight premenopausal women?

Sofiya Alhassan, Alexandre Kiazand, Raymond Balise, Abby C. King, Gerald M. Reaven, Christopher D. Gardner

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The purpose of this analysis was to determine to what extent the clinical criteria for metabolic syndrome (MetSyn) proposed by the World Health Organization (WHO), the European Group for Study of Insulin Resistance (EGIR), the National Cholesterol Education Program Adult Treatment Panel III (ATP III), and the International Diabetes Foundation (IDF); triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio ≥3.0; and enlarged waist circumference (≥88 cm) and elevated TG (≥129 mg/dL) (EWET) identified similar or different overweight women and, secondarily, to examine the effect of 7% weight reduction on MetSyn status. Metabolic syndrome was determined among 256 premenopausal women (age = 41 ± 6 years, body mass index [BMI] = 32 ± 4 kg/m2) participating in a dietary weight loss clinical trial based on the clinical criteria proposed by WHO, EGIR, ATP III, and IDF. The prevalence of TG/HDL-C ratio ≥3.0 and EWET was determined and compared with MetSyn status. Based on the clinical criteria, 16.1% (EGIR), 20.7% (WHO), 31.0% (ATP III), and 31.8% (IDF) of participants met the criteria for MetSyn; 30.3% and 31.8% had TG/HDL-C ≥3.0 and EWET, respectively. Between 77% and 99% of participants were similarly classified across the clinical criteria. The highest and lowest agreements were between ATP III and IDF (κ = 0.98; 95% confidence interval, 0.96-1.0) and WHO and IDF (κ = 0.39; 95% confidence interval, 0.26-0.51), respectively. The TG/HDL-C ratio ≥3.0 and EWET moderately agreed with all 4 clinical criteria for MetSyn (κ range, 0.36-0.59). Among those diagnosed with MetSyn at baseline, 64.0% to 75.0% of the participants who lost ≥7% and 25.8% to 55.6% of participants who lost <7% of their baseline body weight in 6 months no longer met the various clinical criteria for MetSyn, TG/HDL-C ≥3.0, or EWET. Our findings indicate that MetSyn varies substantially between clinical criteria, which raise questions about the clinical utility of these criteria. Regardless of MetSyn clinical criteria, ≥7% reduction in body weight has a beneficial impact on variables used to define MetSyn.

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalMetabolism: Clinical and Experimental
Volume57
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Triglycerides
HDL Cholesterol
Insulin Resistance
Weight Loss
Body Weight
Confidence Intervals
Waist Circumference
Therapeutics
Body Mass Index
Cholesterol
Clinical Trials
Education

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Metabolic syndrome : do clinical criteria identify similar individuals among overweight premenopausal women? / Alhassan, Sofiya; Kiazand, Alexandre; Balise, Raymond; King, Abby C.; Reaven, Gerald M.; Gardner, Christopher D.

In: Metabolism: Clinical and Experimental, Vol. 57, No. 1, 01.2008, p. 49-56.

Research output: Contribution to journalArticle

Alhassan, Sofiya ; Kiazand, Alexandre ; Balise, Raymond ; King, Abby C. ; Reaven, Gerald M. ; Gardner, Christopher D. / Metabolic syndrome : do clinical criteria identify similar individuals among overweight premenopausal women?. In: Metabolism: Clinical and Experimental. 2008 ; Vol. 57, No. 1. pp. 49-56.
@article{f750a7ca2750438fb59c3082b9a9e33e,
title = "Metabolic syndrome: do clinical criteria identify similar individuals among overweight premenopausal women?",
abstract = "The purpose of this analysis was to determine to what extent the clinical criteria for metabolic syndrome (MetSyn) proposed by the World Health Organization (WHO), the European Group for Study of Insulin Resistance (EGIR), the National Cholesterol Education Program Adult Treatment Panel III (ATP III), and the International Diabetes Foundation (IDF); triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio ≥3.0; and enlarged waist circumference (≥88 cm) and elevated TG (≥129 mg/dL) (EWET) identified similar or different overweight women and, secondarily, to examine the effect of 7{\%} weight reduction on MetSyn status. Metabolic syndrome was determined among 256 premenopausal women (age = 41 ± 6 years, body mass index [BMI] = 32 ± 4 kg/m2) participating in a dietary weight loss clinical trial based on the clinical criteria proposed by WHO, EGIR, ATP III, and IDF. The prevalence of TG/HDL-C ratio ≥3.0 and EWET was determined and compared with MetSyn status. Based on the clinical criteria, 16.1{\%} (EGIR), 20.7{\%} (WHO), 31.0{\%} (ATP III), and 31.8{\%} (IDF) of participants met the criteria for MetSyn; 30.3{\%} and 31.8{\%} had TG/HDL-C ≥3.0 and EWET, respectively. Between 77{\%} and 99{\%} of participants were similarly classified across the clinical criteria. The highest and lowest agreements were between ATP III and IDF (κ = 0.98; 95{\%} confidence interval, 0.96-1.0) and WHO and IDF (κ = 0.39; 95{\%} confidence interval, 0.26-0.51), respectively. The TG/HDL-C ratio ≥3.0 and EWET moderately agreed with all 4 clinical criteria for MetSyn (κ range, 0.36-0.59). Among those diagnosed with MetSyn at baseline, 64.0{\%} to 75.0{\%} of the participants who lost ≥7{\%} and 25.8{\%} to 55.6{\%} of participants who lost <7{\%} of their baseline body weight in 6 months no longer met the various clinical criteria for MetSyn, TG/HDL-C ≥3.0, or EWET. Our findings indicate that MetSyn varies substantially between clinical criteria, which raise questions about the clinical utility of these criteria. Regardless of MetSyn clinical criteria, ≥7{\%} reduction in body weight has a beneficial impact on variables used to define MetSyn.",
author = "Sofiya Alhassan and Alexandre Kiazand and Raymond Balise and King, {Abby C.} and Reaven, {Gerald M.} and Gardner, {Christopher D.}",
year = "2008",
month = "1",
doi = "10.1016/j.metabol.2007.08.006",
language = "English (US)",
volume = "57",
pages = "49--56",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Metabolic syndrome

T2 - do clinical criteria identify similar individuals among overweight premenopausal women?

AU - Alhassan, Sofiya

AU - Kiazand, Alexandre

AU - Balise, Raymond

AU - King, Abby C.

AU - Reaven, Gerald M.

AU - Gardner, Christopher D.

PY - 2008/1

Y1 - 2008/1

N2 - The purpose of this analysis was to determine to what extent the clinical criteria for metabolic syndrome (MetSyn) proposed by the World Health Organization (WHO), the European Group for Study of Insulin Resistance (EGIR), the National Cholesterol Education Program Adult Treatment Panel III (ATP III), and the International Diabetes Foundation (IDF); triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio ≥3.0; and enlarged waist circumference (≥88 cm) and elevated TG (≥129 mg/dL) (EWET) identified similar or different overweight women and, secondarily, to examine the effect of 7% weight reduction on MetSyn status. Metabolic syndrome was determined among 256 premenopausal women (age = 41 ± 6 years, body mass index [BMI] = 32 ± 4 kg/m2) participating in a dietary weight loss clinical trial based on the clinical criteria proposed by WHO, EGIR, ATP III, and IDF. The prevalence of TG/HDL-C ratio ≥3.0 and EWET was determined and compared with MetSyn status. Based on the clinical criteria, 16.1% (EGIR), 20.7% (WHO), 31.0% (ATP III), and 31.8% (IDF) of participants met the criteria for MetSyn; 30.3% and 31.8% had TG/HDL-C ≥3.0 and EWET, respectively. Between 77% and 99% of participants were similarly classified across the clinical criteria. The highest and lowest agreements were between ATP III and IDF (κ = 0.98; 95% confidence interval, 0.96-1.0) and WHO and IDF (κ = 0.39; 95% confidence interval, 0.26-0.51), respectively. The TG/HDL-C ratio ≥3.0 and EWET moderately agreed with all 4 clinical criteria for MetSyn (κ range, 0.36-0.59). Among those diagnosed with MetSyn at baseline, 64.0% to 75.0% of the participants who lost ≥7% and 25.8% to 55.6% of participants who lost <7% of their baseline body weight in 6 months no longer met the various clinical criteria for MetSyn, TG/HDL-C ≥3.0, or EWET. Our findings indicate that MetSyn varies substantially between clinical criteria, which raise questions about the clinical utility of these criteria. Regardless of MetSyn clinical criteria, ≥7% reduction in body weight has a beneficial impact on variables used to define MetSyn.

AB - The purpose of this analysis was to determine to what extent the clinical criteria for metabolic syndrome (MetSyn) proposed by the World Health Organization (WHO), the European Group for Study of Insulin Resistance (EGIR), the National Cholesterol Education Program Adult Treatment Panel III (ATP III), and the International Diabetes Foundation (IDF); triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio ≥3.0; and enlarged waist circumference (≥88 cm) and elevated TG (≥129 mg/dL) (EWET) identified similar or different overweight women and, secondarily, to examine the effect of 7% weight reduction on MetSyn status. Metabolic syndrome was determined among 256 premenopausal women (age = 41 ± 6 years, body mass index [BMI] = 32 ± 4 kg/m2) participating in a dietary weight loss clinical trial based on the clinical criteria proposed by WHO, EGIR, ATP III, and IDF. The prevalence of TG/HDL-C ratio ≥3.0 and EWET was determined and compared with MetSyn status. Based on the clinical criteria, 16.1% (EGIR), 20.7% (WHO), 31.0% (ATP III), and 31.8% (IDF) of participants met the criteria for MetSyn; 30.3% and 31.8% had TG/HDL-C ≥3.0 and EWET, respectively. Between 77% and 99% of participants were similarly classified across the clinical criteria. The highest and lowest agreements were between ATP III and IDF (κ = 0.98; 95% confidence interval, 0.96-1.0) and WHO and IDF (κ = 0.39; 95% confidence interval, 0.26-0.51), respectively. The TG/HDL-C ratio ≥3.0 and EWET moderately agreed with all 4 clinical criteria for MetSyn (κ range, 0.36-0.59). Among those diagnosed with MetSyn at baseline, 64.0% to 75.0% of the participants who lost ≥7% and 25.8% to 55.6% of participants who lost <7% of their baseline body weight in 6 months no longer met the various clinical criteria for MetSyn, TG/HDL-C ≥3.0, or EWET. Our findings indicate that MetSyn varies substantially between clinical criteria, which raise questions about the clinical utility of these criteria. Regardless of MetSyn clinical criteria, ≥7% reduction in body weight has a beneficial impact on variables used to define MetSyn.

UR - http://www.scopus.com/inward/record.url?scp=37049006915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37049006915&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2007.08.006

DO - 10.1016/j.metabol.2007.08.006

M3 - Article

C2 - 18078858

AN - SCOPUS:37049006915

VL - 57

SP - 49

EP - 56

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -